| A multicenter, randomized, open-label, phase II trial of erlotinib versus etoposide plus cisplatin with concurrent radiotherapy in unresectable stage III non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating m | |
| Xing, Ligang; Wu, Gang; Wang, Lvhua; Li, Jian-Cheng; Wang, Jianhua; Yuan, Zhiyong; Chen, Ming; Xu, Yaping; Zhu, Zhengfei; Lu, You | |
| 2017 | |
| 会议名称 | JOURNAL OF CLINICAL ONCOLOGY |
| 会议日期 | 2017-05-20 |
| 收录类别 | CPCI-S |
| URL标识 | 查看原文 |
| 内容类型 | 会议论文 |
| URI标识 | http://www.corc.org.cn/handle/1471x/6369373 |
| 专题 | 中国医学科学院 北京协和医学院 |
| 推荐引用方式 GB/T 7714 | Xing, Ligang,Wu, Gang,Wang, Lvhua,et al. A multicenter, randomized, open-label, phase II trial of erlotinib versus etoposide plus cisplatin with concurrent radiotherapy in unresectable stage III non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating m[C]. 见:JOURNAL OF CLINICAL ONCOLOGY. 2017-05-20. |
| 个性服务 |
| 查看访问统计 |
| 相关权益政策 |
| 暂无数据 |
| 收藏/分享 |
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
修改评论